ARTICLE | Clinical News
FDA extends review of Tecentriq/Avastin combo for NSCLC
September 7, 2018 6:07 PM UTC
Roche (SIX:ROG; OTCQX:RHHBY) said FDA extended review for an sBLA for Tecentriq atezolizumab by three months to Dec. 5. The original PDUFA date was Sept. 5. The sBLA , which FDA is evaluating under Priority Review, is for Tecentriq in combination with Avastin bevacizumab, paclitaxel and carboplatin as first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) (see "Priority Review for Roche's Tecentriq in First-Line NSCLC").
Roche said the extension is to allow FDA time to review additional information requested in support of the sBLA, but did not provide details...
BCIQ Company Profiles
BCIQ Target Profiles